Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Pugh

Showing results (201-210 of 224) with videos related to

Pageof 23
Sort By:
JAMA Oncology|January 19, 2017
Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525Erica Hlavin Bell, Stephanie L Pugh, Joseph P McElroy, et al.
International Journal of Radiation Oncology, Biology, Physics|June 19, 2018
Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate CancerHimanshu R Lukka, Stephanie L Pugh, Deborah W Bruner, et al.
International Journal of Radiation Oncology, Biology, Physics|April 7, 2020
Phase 2 Study of a Temozolomide-Based Chemoradiation Therapy Regimen for High-Risk, Low-Grade Gliomas: Long-Term Results of Radiation Therapy Oncology Group 0424Barbara J Fisher, Stephanie L Pugh, David R Macdonald, et al.
JCO Precision Oncology|September 30, 2021
Long-Term Report of a Comprehensive Molecular and Genomic Analysis in NRG Oncology/RTOG 0424: A Phase II Study of Radiation and Temozolomide in High-Risk Grade II GliomaJessica L Fleming, Stephanie L Pugh, Barbara J Fisher, et al.
International Journal of Radiation Oncology, Biology, Physics|May 13, 2024
Validation of Patient-Reported Outcomes in Patients With Nonmetastatic Breast Cancer Receiving Comprehensive Nodal Irradiation in the RadComp TrialElizabeth A Hahn, Stephanie L Pugh, Hien L Lu, et al.
Plos One|April 14, 2021
Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415Rahul Khairnar, Stephanie L Pugh, Howard M Sandler, et al.
The New England Journal of Medicine|February 2, 2017
Radiation with or without Antiandrogen Therapy in Recurrent Prostate CancerWilliam U Shipley, Wendy Seiferheld, Himanshu R Lukka, et al.
JCO Clinical Cancer Informatics|May 9, 2025
Assessing Algorithmic Fairness With a Multimodal Artificial Intelligence Model in Men of African and Non-African Origin on NRG Oncology Prostate Cancer Phase III TrialsMack Roach, Jingbin Zhang, Osama Mohamad, et al.
Journal of Neuro-Oncology|November 11, 2021
Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825Nirav Patil, Eashwar Somasundaram, Kristin A Waite, et al.
JCO Precision Oncology|July 8, 2026
Participant Heterogeneity in the Prostate Cancer Biobank of the NRG: An Obstacle to Broadening the Reach of Precision OncologySophia C Kamran, Monica Borges, Jeff Michalski, et al.
Pageof 23

Showing results (201-210 of 224) with videos related to

Sort By:
Pageof 23
JAMA Oncology|January 19, 2017
Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525Erica Hlavin Bell, Stephanie L Pugh, Joseph P McElroy, et al.
International Journal of Radiation Oncology, Biology, Physics|June 19, 2018
Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate CancerHimanshu R Lukka, Stephanie L Pugh, Deborah W Bruner, et al.
International Journal of Radiation Oncology, Biology, Physics|April 7, 2020
Phase 2 Study of a Temozolomide-Based Chemoradiation Therapy Regimen for High-Risk, Low-Grade Gliomas: Long-Term Results of Radiation Therapy Oncology Group 0424Barbara J Fisher, Stephanie L Pugh, David R Macdonald, et al.
JCO Precision Oncology|September 30, 2021
Long-Term Report of a Comprehensive Molecular and Genomic Analysis in NRG Oncology/RTOG 0424: A Phase II Study of Radiation and Temozolomide in High-Risk Grade II GliomaJessica L Fleming, Stephanie L Pugh, Barbara J Fisher, et al.
International Journal of Radiation Oncology, Biology, Physics|May 13, 2024
Validation of Patient-Reported Outcomes in Patients With Nonmetastatic Breast Cancer Receiving Comprehensive Nodal Irradiation in the RadComp TrialElizabeth A Hahn, Stephanie L Pugh, Hien L Lu, et al.
Plos One|April 14, 2021
Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415Rahul Khairnar, Stephanie L Pugh, Howard M Sandler, et al.
The New England Journal of Medicine|February 2, 2017
Radiation with or without Antiandrogen Therapy in Recurrent Prostate CancerWilliam U Shipley, Wendy Seiferheld, Himanshu R Lukka, et al.
JCO Clinical Cancer Informatics|May 9, 2025
Assessing Algorithmic Fairness With a Multimodal Artificial Intelligence Model in Men of African and Non-African Origin on NRG Oncology Prostate Cancer Phase III TrialsMack Roach, Jingbin Zhang, Osama Mohamad, et al.
Journal of Neuro-Oncology|November 11, 2021
Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825Nirav Patil, Eashwar Somasundaram, Kristin A Waite, et al.
JCO Precision Oncology|July 8, 2026
Participant Heterogeneity in the Prostate Cancer Biobank of the NRG: An Obstacle to Broadening the Reach of Precision OncologySophia C Kamran, Monica Borges, Jeff Michalski, et al.
Pageof 23